Vaccine hesitancy in the US may have implications for investment. The issue is part of a broader global context, where outbreaks of vaccine-preventable diseases are threatening progress. The situation is complex, with various factors and stakeholders involved, including potential impacts on pharmaceutical companies and global health initiatives.